Predictors for non-relapsing status in methadone-maintained heroin addicts. A long-term perspective study

Heroin Addiction and Related Clinical Problems

Volumn 10, Issue 4, 2008, Pages 19-28

  Maremmani, Icro ^a,b,c,g   Pacini, Matteo ^a,c   Lamanna, Francesco ^a   Pani, Pier Paolo ^d   Trogu, Manuela ^d   Perugi, Giulio ^a,c   Deltito, Joseph ^c,e   Gerra, Gilberto ^f  

^a UNIVERSITY OF PISA   (Italy)

^b AU CNS   (Italy)

^c G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^d Sardinia Health and Social Administration   (Italy)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f UNITED NATIONS   (United States)

^g UNIVERSITY OF PISA   (Italy)

Author keywords

Methadone treatment; Psychiatric comorbidity; Response predictors to treatment outcome; Retention

Indexed keywords

ANTIDEPRESSANT AGENT; METHADONE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS;

EID: 58349118254     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. BALL J. C., LANGE W. R., MYERS C. P., FRIEDMAN S. R. (1988): Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behavior. 29 214-226.
2. BALL J. C., ROSS C. A. (1991): The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York.
3. CACCIOLA S. J., ALTERMAN A. I., RUTHERFORD M. J., MCKAY J. R., MULVANEY F. D. (2001): The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 61 271-280.
4. CONDELLI W. S. (1993): Strategies for increasing retention in methadone programs. J Psychoactive Drugs. 25 143-147.
5. COOPER J. R. (1989): Methadone treatment and acquired immuno-deficiency syndrome. JAMA. 262 1664-1668.
6. DARKE S., ROSS J., MILLS K. L., WILLIAMSON A., HAVARD A., TEESSON M. (2007): Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addict Behav. 32:(9) 1897-1906.
7. DOLE V. P., NYSWANDER M. E., DE JERLAIS D., JOSEPH H. (1982): Sounding board: Performance-based rating of methadone maintenance programs. N Engl J Med. 306 169-172.
8. EMRICH H. M., VOGT P., HERZ A. (1982): Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 398 108-112.
9. EPSTEIN D. H., PRESTON K. L. (2003): Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 98:(3) 269-279.
10. EXTEIN I., POTTASH A. L. C., GOLD M. S. (1982): A possible opioid receptor dysfunction in some depressive disorders. Ann N Y Acad Sci. 398 113-119.
11. FARLEY T. A., CARTTER M. L., WASSELL J. T., HADLER J. L. (1994): Predictors of outcome in methadone programs: effect of HIV counseling and testing. Conn Med. 58:(3) 165-171.
12. GASQUET I., LANCON C., PARQUET P. (1999): Predictive factors for patient maintenance on buprenorphine high dosage treatment: a naturalistic study in primary care. . Encephale. 25:(6) 645-651.
13. GELKOPF M., WEIZMAN T., MELAMED Y., ADELSON M., BLEICH A. (2006): Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci. 43:(2) 126-136.
14. GERRA G., BORELLA F., ZAIMOVIC A., MOI G., BUSSANDRI M., BUBICI C., BERTACCA S. (2004): Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75:(1) 37-45.
15. GOEHL L., NUNES E., QUITKIN F., HILTON I. (1993): Social networks and methadone treatment outcome: the costs and benefits of social ties. Am J Drug Alcohol Abuse. 19:(3) 251-262.
16. GOLD M. S., POTTASH A. L. C., SWEENEY D. R., MARTIN D., EXTEIN I. (1982): Antimanic, antidepressant, and antipanic effects of opiate: clinical, neuro-anatomical, and biochemical evidence. Ann N Y Acad Sci. 398 140-150.
17. GOSSOP M., MARSDEN J., STEWART D. (2006): Remission of psychiatric symptoms among drug misusers after drug dependence treatment. J Nerv Ment Dis. 194:(11) 826-832.
18. HIEN D. A., NUNES E., LEVIN F. R., FRASER D. (2000): Posttraumatic stress disorder and short-term outcome in early methadone treatment. J Subst Abuse Treat. 19:(1) 31-37.
19. HSER Y. I., ANGLIN M. D., FLETCHER B. (1998): Comparative treatment effectiveness. Effects of program modality and client drug dependence history on drug use reduction. J Subst Abuse Treat. 15:(6) 513-523.
20. HUBBARD R. L., MARSDEN M. E., RACHAL J. V., HARWOOD H. J., CAVANAUGH E. R., GINZBURG H. M. (1989): Drug abuse treatment: A national study of effectiveness. The University of North Carolina, Chapel Hill.
21. KHANTZIAN E. J. (1980): An ego/self theory of substance dependence: a contemporary psychoanalitic perspective. Nida Res Monogr. 30 184-191.
22. KHANTZIAN E. J. (1982): Psychological (structural) Vulnerabilities and the Specific Appeal of Narcotics. Ann N Y Acad Sci. 398 24-32.
23. KIDORF M., KING V. L., NEUFELD K., STOLLER K. B., PEIRCE J., BROONER R. K. (2005): Involving significant others in the care of opioid-dependent patients receiving methadone. J Subst Abuse Treat. 29:(1) 19-27.
24. KOSTEN T. R., ROUNSAVILLE B. J., KLEBER H. D. (1986): A 2.5 year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 43 733-738.
25. KOSTEN T. R., ROUNSAVILLE B. J., KLEBER H. D. (1987): Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income. Am J Drug Alcohol Abuse. 13:(1-2) 19-32.
26. LEAVITT S. B., SHINDERMAN M., MAXWELL S., EAP C. B., PARIS P. (2000): When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 67:(5-6) 404-411.
27. MAGURA S., NWAKEZE P. C., DEMSKY S. Y. (1998): Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 93:(1) 51-60.
28. MAGURA S., NWAKEZE P. C., KANG S. Y., DEMSKY S. (1999): Program quality effects on patients outcomes during methadone maintenance: a study of 17 clinics. J Subst Use Misuse. 34:(9) 1299-1324.
29. MAREMMANI I., CASTROGIOVANNI P. (1989): DAH-RS: Drug Addiction History Rating Scale. University Press, Pisa.
30. MAREMMANI I., PACINI M., LUBRANO S., LOVRECIC M. (2003): When 'enough' is still not 'enough'. Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 5:(1) 17-32.
31. MAREMMANI I., ZOLESI O., AGLIETTI M., MARINI G., TAGLIAMONTE A., SHINDERMAN M. S., MAXWELL S. (2000): Methadone Dose and Retention in Treatment of Heroin Addicts with Axis I Psychiatric Comorbidity. J Addict Dis. 19:(2) 29-41.
32. MASON B. J., KOCSIS J. H., MELIA D., KHURI E. T., SWEENEY J., WELLS A., BORG L., MILLMAN R. B., KREEK M. J. (1998): Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 17:(3) 75-89.
33. MCKENNA G. J. (1982): Methadone and opiate drugs: psychotropic effects and self medication. Ann N Y Acad Sci. 398 44-55.
34. MCLELLAN A. T., ALTERMAN A. I., METZGER D. S., GRISSOM G. R., WOODY G. E., LUBORSKY L., O'BRIEN C. P. (1994): Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. J Consult Clin Psychol. 62:(6) 1141-1158.
35. OSBORN E., GREY C., REZNIKOFF M. (1986): Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment. Am J Drug Alcohol Abuse. 12:(4) 383-388.
36. PACINI M., MAREMMANI I. (2005): Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and/or acute psychotic episodes. Heroin Addict Relat Clin Probl. 7:(4) 43-48.
37. PANI P. P., PIRASTU R., RICCI A., GESSA G. L. (1996): Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. Drug Alcohol Depend. 41 81-84.
38. PANI P. P., TROGU E., CONTU P., AGUS A., GESSA G. L. (1997): Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program. Drug Alcohol Depend. 48 119-126.
39. PELES E., SCHREIBER S., ADELSON M. (2006): Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 82:(3) 211-217.
40. POIRIER M. F., LAQUEILLE X., JALFRE V., WILLARD D., BOURDEL M. C., FERMANIAN J., OLIE J. P. (2004): Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients. Prog Neuropsychopharmacol Biol Psychiatry. 28:(2) 267-272.
41. PRESTON K. L., SILVERMAN K., HIGGINS S. T., BROONER R. K., MONTOYA I., SCHUSTER C. R., CONE E. J. (1998): Cocaine use early in treatment predicts outcome in a behavioral treatment program. J Consult Clin Psychol. 66:(4) 691-696.
42. ROUNSAVILLE B. J., KOSTEN T. R., KLEBER H. D. (1986): Long-term changes in current psychiatric diagnoses of treated opiate addicts. Compr Psychiatry. 27 480-498.
43. ROUNSAVILLE B. J., KOSTEN T. R., WEISSMAN M. M., KLEBER H. D. (1986): Prognostic significance of psychopathology in treated opioid addicts: a 2.5-year follow-up study. Arch Gen Psychiatry. 43 379-345.
44. ROUNSAVILLE B. J., TIERNEY T., CRITSCHRISTOPH K., WEISSMAN M. M., KLEBER H. B. (1982): Predictors of outcome in treatment of opiate addicts: Evidence for the multidimensional nature of addicts' problems. Compr Psychiatry. 23 462-478.
45. ROUNSAVILLE B. J., WEISSMAN M. M., CRITSCHRISTOPH K., WILBER C., KLEBER H. (1982): Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 39:(2) 151-156.
46. RUTHERFORD M. J., CACCIOLA J. S., ALTERMAN A. I., COOK T. G. (1997): Social competence in opiate-addicted individuals: gender differences, relationship to psychiatric diagnoses, and treatment response. Addict Behav. 22:(3) 419-425.
47. SIMPSON D. D. (1979): The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry. 136:(11) 1449-1453.
48. SIMPSON D. D. (1981): Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch Gen Psychiatry. 38:(8) 875-880.
49. SIMPSON D. D., JOE G. W., ROWAN-SZAL G. A. (1997): Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 47:(3) 227-235.
50. STRAIN E. C., STITZER M. L., LIEBSON I. A., BIGELOW G. E. (1993): Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 119:(1) 23-27.
51. STRAIN E. C., STITZER M. L., LIEBSON I. A., BIGELOW G. E. (1993): Methadone dose and treatment outcome. Drug Alcohol Depend. 33:(2) 105-117.
52. TORRENS M., CASTILLO C., PEREZ-SOLA V. (1996): Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 41:(1) 55-59.
53. VEREBEY K. E. (1982): Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann N Y Acad Sci. 398.
54. VILLAFRANCA S. W., MCKELLAR J. D., TRAFTON J. A., HUMPHREYS K. (2006): Predictor of retention in methadone programs: A signal detection analysis. Drug Alcohol Depend. 83 218-224.
55. WURMSER L. (1974): Psychoanalytic considerations of the etiology of compulsive drug use. J Am Psychoanal Assoc. 22:(4) 820-843.